An Uncontrolled, Open-Label Extension Study to Evaluate the Long Term Safety, Tolerability, and Maintenance of Effect of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Next Previous
Trial Profile

An Uncontrolled, Open-Label Extension Study to Evaluate the Long Term Safety, Tolerability, and Maintenance of Effect of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Vixotrigine (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions
  • Sponsors Biogen; Convergence Pharmaceuticals

    • Most Recent Events

    • 14 Mar 2018 Planned End Date changed from 22 Jul 2020 to 22 Aug 2019.
    • 14 Mar 2018 Planned primary completion date changed from 22 Jul 2020 to 22 Aug 2019.
    • 01 Dec 2017 Planned End Date changed from 28 Feb 2019 to 22 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top